Intubation is the sometimes-tricky placement of a plastic tube into the lungs
that allows anesthetized or critically ill patients to breathe. The standard
procedure requires the physician to see the trachea and choose between two very
similar holes, one leading to the lungs and the other to the stomach. Failure to
identify the correct one can kill the patient. In addition, intubation sometimes
has to be carried out on the battlefield, or on patients who have blood or
liquids obstructing the way. But now, students in the biodesign program of the
Hebrew University of Jerusalem and Hadassah University Medical Center in
Jerusalem’s Ein Kerem have designed a self-guided robotic intubation device that
crawls to the lungs in difficult situations.
The “GuideIN Tube” is a
robotic intubation device that automatically identifies the lungs using
an i n f r a r e d source and navigates toward it. The device was successfully
tested on cadavers at Hadassah, and clinical trials will begin as soon as next
“I strongly believe that GuideIn Tube represents the future of
intubation,” said Dr. Elchanan Fried, director of the hospital’s general
intensive care unit and the group’s clinical expert. The device targets a $3
billion market, which is expected to increase by five percent a year.
really thought about the paramedic in the field,” said Itai Hayut, the leading
engineering student on the project. “We wanted something simple and compact that
they could trust without fail. I think we hit it on all marks.” Other students
in the group include Tommy Weiss-Sadan, a biology graduate student, as well as
Sarah Horwitz and Ariel Shrem who are completing their MBA
Biodesign is a multidisciplinary, team-based approach to medical
innovation, created by the HU and the Hadassah University Medical Center in
partnership with Stanford University. The program takes outstanding medical
fellows, bioengineering and business graduate students, and tutors them in the
science and practice of bringing a medical innovation to the market. The program
is directed by Dr. Yaakov Nahmias, head of the HU bioengineering program and
Prof. Chaim Lotan, director of Hadassah’s heart institute.
OF ORAL CANCER MORE EFFECTIVE
Smoking and drinking alcohol are two of the main
causes of cancer in the mouth and throat, but there are also genetic, geographic
and cultural factors. Recently it was discovered to exposure to the human
papilloma virus – contracted during oral sex – is also increasingly involved in
Treatment includes surgery, chemotherapy and
Survival from this type of malignant tumor in past decades
reached only 50 percent. But new international research headed by doctors from
Haifa’s Rambam Medical Center has shown that in the past decade, the mortality
rate from oral cancer has declined by 12% – from 31% to 19% – even though more
patients were treated at an advanced stage and a later age than before. For
example, during the past 10 years, 14% of those treated were over 70, compared
to only 10% a decade before. Over half had advanced tumors in the past decade,
compared to 45% 10 years before that.
Prof. Ziv Gil, head of the
ear-noseand- throat (ENT) department at Rambam, and his department colleague Dr.
Moran Amit, worked with leading oncology departments in Italy, Australia,
Brazil, Germany, India, the US and Taiwan. Their article will be published in
the prestigious journal Cancer.
Responsible for the lower death rates,
the researchers concluded, was that clinicians have taken a multidisciplinary
approach to oral cancer that includes choice of the treatment best suited to the
patient, dealing with complications during or after surgery and using procedures
for rehabilitation of function after treatment. Such an approach is uniquely
possible, said Gil, in public university medical centers were teams from a
variety of specialties are available. They are thus much more successful in
fighting the cancer than a single oncologist or ENT specialist. Gil concluded
that followup of the patient is required for years after initial treatment,
preferably by the same team that originally treated him.
A new analysis has found that breastfeeding for more than six months
may safeguard nonsmoking mothers against breast cancer – but does not offer the
same protection to mothers who smoked. Published in the online edition of the
Journal of Clinical Nursing, the findings add to the list of benefits of
breastfeeding for women and their babies.
To examine the relationship
between breast cancer and certain aspects of pregnancy and breastfeeding, Dr.
Emilio González- Jiménez of Spain’s University of Granada in Spain and his
colleagues analyzed the medical records of 504 female patients who were 19 to 91
years of age and who had been diagnosed and treated for breast cancer from 2004
to 2009 at the San Cecilio University Hospital in Granada. The team looked at
factors including age of diagnosis, how long the women breastfed, family history
of cancer, obesity, alcohol consumption and smoking habits.
analysis revealed that women who underwent childbirth and breastfed were
diagnosed with breast cancer at a later age, regardless of the patients’ family
history of cancer. Nonsmokers who breastfed for periods of longer than six
months tended to be diagnosed with breast cancer much later in life – an average
of 10 years later than nonsmokers who breastfed for a shorter period. In
contrast, female smokers were diagnosed with breast cancer at a younger age and
obtained no significant benefit from a longer period of
“The results suggest that for nonsmokers, breastfeeding
for more than six months not only provides children with numerous health
benefits, but it also may protect mothers from breast cancer,” said